A review on current research status of the surface modification of Zn-based biodegradable metals

Wei Yuan a, Dandan Xia a, b, Shuilin Wu c, Yufeng Zheng a, b, *, Zhenpeng Guan d, **, Julietta V. Rau e, f, ***

a School of Materials Science and Engineering, Peking University, Beijing, 100871, China
b National Engineering Laboratory for Digital and Material Technology of Stomatologia, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatologia, National Medical Products Administration Key Laboratory for Dental Materials, Research Center of Engineering and Technology for Digital Dentistry, Ministry of Health, Beijing, 100081, China
c National Engineering Laboratory for Digital and Material Technology of Stomatologia, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatologia, National Medical Products Administration Key Laboratory for Dental Materials, Research Center of Engineering and Technology for Digital Dentistry, Ministry of Health, Beijing, 100081, China
d Orthopedics Department, Peking University Shougang Hospital, No. 9 Jinyuanzhuang Rd, Shijingshan District, Beijing, 100144, China
e Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche (ISM-CNR), Via del Fosso del Cavaliere, 100-00133, Rome, Italy
f Sechenov First Moscow State Medical University, Institute of Pharmacy, Department of Analytical, Physical and Colloid Chemistry, Trubetskaya 8, build. 2, 119991, Moscow, Russia

1. Brief review on industrial Zn alloys and their surface modification methods

Date back to early 20th century, industrial Zn alloys were developed firstly and applied as a replacement for tin and lead alloys in pressure die casting of printing type [1]. Various alloying elements have been added into Zn to further optimize the performance. Among them, Al was regarded as an advantageous element in the initial stage. It can improve the fluidity of melt as well as the mechanical properties of alloys [2]. Hence, Zn-Al system has been developed as the basis of most commercial alloys in casting industries. In terms of industrial applications, Zn and its alloys have been widely used in the protection of steel against corrosion [3,4]. Almost half of the production of Zn comes into service for coatings [5]. Different methods have been adopted to prepare the Zn coatings including hot-dip galvanizing (HDG), electroplating, metalizing, mechanical plating and Zn rich paint [6]. Among them, HDG is considered as a specifically effective and efficient method for the application of Zn coatings due to its convenience and high cost performance. Since 1800, HDG technique has been confirmed as a feasible approach subsequent to the exploration of iron and zinc [6]. The process...
involves immersion of the steel in the melt Zn, resulting in a sufficient coverage of Zn coatings. The galvanized Zn coatings can protect the steel substrate from the attack of aggressive corrosion media as physical barriers [7]. On the one hand, Zn is able to interact with the atmospheric compounds and forms a layer of dense, adherent and protective film on the coating surface. On the other hand, Zn also retards the corrosion of substrate thanks to the cathodic protective nature [8]. Nonetheless, the galvanized Zn coatings are apt to be damaged under the condition of wet, industrial or marine environment [5]. Meanwhile, note that the galvanized steel is usually painted, pretreatment is generally required for a better adhesion promoter [9]. Therefore, many attempts have been made to optimize the constituents of Zn coatings and improve the lifetime of Zn coatings. Alloying Zn with other elements such as Co, Ni, Fe and Mn can be an efficient way to further improve the protective effect of Zn coatings [10–12]. Besides, surface modification has also been adopted to improve the corrosion resistance of Zn coatings, mainly including chemical conversion coatings and organic coatings. The representative surface modification methods of Zn-based alloys for industrial applications are illustrated in Fig. 1.

1.1. Chemical conversion coatings

The formation of chemical conversion coatings involves a complex process of metal dissolution and precipitation, which usually proceeds in the aqueous solution [21]. The treatment is aimed at replacement of the native oxide layer of less corrosion resistance [22]. Chemical conversion coatings consist of the mixtures of different metal oxides and hydroxides dependent on the dissolved ions in the bath solution besides the zinc oxides and hydroxides [23]. Such conversion coatings can achieve tight adherence to the substrate due to the nature of chemical bonding as well as an improved corrosion resistance.

(1) Chromate conversion coatings

The chromate-based coatings have been widely used for the improvement of the corrosion resistance of metals as well as the adhesion of paints and lacquers in industrial system [13]. The formation of chromate conversion coatings involves a series of complex reactions [24]. The fundamental process can be summarized as the redox reaction between Zn matrix and Cr(VI) ions in the bath solution [24]. At the initial stage, Zn dissolves into Zn$^{2+}$ in the acid treatment solution. Subsequently, the precipitation of Cr(III) forms and adheres on the surface, which is associated with the local pH increase attributed to the consumption of hydrogen ions during the reduction of Cr(VI). At the end, a conversion coating consisting of zinc oxides and hydroxides, zinc chromate, mixed Cr(III) and Cr(VI) oxides and hydroxides would be generated on the surface [25]. The insoluble components of chromate conversion coatings can effectively protect the substrate from the corrosion medium as physical barriers [13]. In addition, the chromate conversion coatings are also claimed to provide self-healing ability to metallic substrate under the circumstance of defect or failure. The water-soluble Cr(VI)-containing components in the coatings are able to migrate to the position of scratch and defect, where they would be reduced to form a passivation layer. Under this condition, the amount of the soluble Cr(VI) species which are absorbed onto or exist within the coatings after the chromating treatment plays a significant role in the corrosion protection [13,26,27].

Nevertheless, it is claimed that Cr(VI) chemicals used in the conversion treatment are toxic and carcinogenic [13]. Hence, much attention has been focused on the development of non-chromate passivation treatments. Cr(III)-based conversion coatings have been put forward as potential alternatives to the Cr(VI)-based conversion coatings on account of their comparable corrosion resistance but better biocompatibility [28]. Meanwhile, the preparation process of Cr(III) conversion coatings is similar to that of chromate counterpart in the industries [29]. The corrosion resistance of Cr(III) conversion coating, fabricated in the treatment solution containing nitrate as an oxidant and sodium...
Bioactive Materials 7 (2022) 192–216

W. Yuan et al.

194

conversion process to improve the surface properties, such as the corrosion resistance of trivalent chromate conversion coatings [32, 33]. Nonetheless, the Cr(III) conversion coatings lack for the self-healing property in case of coating defect compared with the chromate coatings [29].

(2) Phosphate conversion coatings

The Zn phosphating is one of the most commonly used chemical conversion process to improve the surface properties, such as the corrosion resistance, wear reduction and adhesion for painting in industries [34]. Generally, phosphating treatment is conducted in acid phosphate aqueous solutions containing ZnSO₄ and H₂PO₄ as well as NO₃⁻ and NO₂⁻ as accelerators [35]. The phosphating reaction begins with the dissolution of Zn and air-formed oxide/hydroxide film upon immersion in the acid bath. Subsequently, the protons are reduced and consumed, resulting in the local pH increase near the Zn electrode surface. Meanwhile, pH increase promotes the dissociation of H₂PO₄ and HPO₄²⁻. Thereafter, hopeite, the major component of the corrosion protection layer, deposits on the surface once the local pH is high enough [14]. The crystalline phosphate salts continue growing and cover the whole surface until being stopped by self-inhibition [36]. Although the hopeite crystals adhere well on the Zn-coated surface, irregular crystal shape results in the presence of open pores, which make it accessible for the corrosion attack [37]. In this way, the corrosion resistance of phosphate conversion coating is directly related to the coating porosity. Many efforts have been made to optimize the structure of phosphate crystals, decrease the grain size and improve the coating coverage. It is reported that pretreatment with colloidal titanium phosphate solution can increase the nucleation sites of hopeite during Zn phosphating [36,38,39]. In addition, incorporation of additives in the treatment solution, such as Mg²⁺ [40,41], Ni²⁺ [35,42,43] and Mn²⁺ [44], can also decrease the corrosion porosity and improve the corrosion resistance. Tsai et al. [40] reported that addition of Mg²⁺ into phosphate solution reduced the phosphate grain size and increased population density of grains, resulting in better corrosion protection. The same grain refinement effect of Mg²⁺ has also been reported by Ishizuka et al. [41]. The incorporation of Ni²⁺ can modify the nucleation and growth rate of phosphate crystals in addition to the formation of Zn-Ni alloy on the bottom of pores [35]. Besides, silicate post-treatment can seal the pores in the phosphate conversion coatings and form continuous composite coatings, leading to increased corrosion resistance [45]. Lin et al. [46] demonstrated that post-treatment with molybdate solution was able to form dense and complete composite coatings on the surface, inhibiting both the anodic and cathodic process of Zn corrosion.

(3) Molybdate conversion coatings

Molybdenum, presented as an additive in electrolyte or alloying element, can effectively inhibit the corrosion of metals such as aluminum, zinc and steel as an environmental-friendly and effective corrosion inhibitor [47–50]. Molybdate conversion coatings have also been reported to offer an efficient inhibitor to improve the corrosion protection due to their low toxicity. Molybdate-based passive films can be generated by immersion or with applied cathodic potential [15,51]. Generally, the protective effect of the conversion coatings rest on the coating thickness and compactness [15]. However, the molybdate conversion coatings are generally characterized by cracked “dried riverbed” morphology [52]. It is reported that the pH value of the treatment solution and applied acid used to adjust pH value play a significant role in the coating quality. The prepared film can provide a superior protection when the pH values range from 1 to 6 for any acid [53]. Magalhães et al. [53] demonstrated that Zn electrodes treated in the molybdate bath acidified with phosphoric acid exhibited better corrosion protection compared with those acidified with sulfuric acid and nitric acid.

(4) Vanadate conversion coatings

Vanadates have been considered as effective corrosion inhibitors to suppress the corrosion of Zn in aqueous solution [54,55]. Meanwhile, vanadate conversion coatings have been widely applied on the surface of Zn or HGD steel for the sake of corrosion protection [56–58]. It is claimed that the corrosion inhibitory effect is possibly attributed to the existence of the +4/+5 mixed oxidation state of the conversion coatings [59]. Zou et al. [16] constructed vanadium conversion coating, which is mainly composed of closely packed particles of V₂O₅, VO₂ and their hydrates on the surface of electrogalvanized steel. They found superior corrosion resistance of vanadate-treated samples compared with that of untreated and chromate-treated samples.

(5) Rare earth metal salts conversion coatings

Rare earth (RE) salts have been proposed as promising corrosion inhibitors on a variety of metals [60–63]. It is reported that rare earth compounds can improve the corrosion resistance of metals by constructing a layer of protection film on the metallic surface [64–66]. Local alkaline environment by reason of oxygen reduction leads to the precipitation of RE oxides/hydroxides on the cathodic areas of metals [67–69]. The immersion of Zn in the aqueous solution of Ce(NO₃)₂ is able to form a layer of passive film mainly consisting of oxides and hydroxides of Ce(III) and Ce(IV) [66]. Meanwhile, cerium conversion coating modified with Ce(NO₃)₃·6H₂O exhibited favorable self-sealing property [70]. Ce³⁺ in the coating can migrate to the scratch and cover the damaged sites with the precipitation of Ce(OH)₃ or CeO₂. Zhang et al. [71] reported that the lanthanum salt conversion coating, mainly composed of La(OH)₃·La₂O₃ and Zn(OH)₂·ZnO, was prepared on the surface of HDG steel, resulting in improved corrosion resistance. Montemor et al. [69] compared the effects of different RE conversion coatings on galvanized steel by immersion in the nitrate solutions of RE metals (cerium, yttrium and lanthanum). Although all the conversion coatings exhibited beneficial effects, the coating fabricated in the lanthanum nitrate solution showed the best corrosion protection. Moreover, modifying the rare earth conversion coatings with organic and inorganic inhibitors can further improve the protection performance of coatings. Gang et al. [72] demonstrated better corrosion resistance of lanthanum salt conversion coating when modified with citric acid.

(6) Silicate conversion coatings

On account of its superior inhibitory effect and high cost-effectiveness, sodium silicate is well known as the inhibitor and passivator to retard the corrosion process of metals [50,73]. Meanwhile, many researches have proposed silicate and silica as environmental-friendly and corrosion-resistant coatings on galvanized steel [17,74–77]. Yuan et al. [78] constructed silicate conversion coatings on HDG steel in a sodium silicate solution with SiO₂Na₄O molar ratio ranging from 1.00 to 4.00. The conversion coating fabricated with a molar ratio of 3.50 showed the optimum corrosion resistance with more compact and uniform structure. Jamali et al. [79] deposited nano-silica potassium silicate conversion coatings on HDG steel. They found that the silica nanoparticles can fill the pores among the potassium silicate coating due to the fine particle size, giving rise to the improvement of corrosion resistance. In addition, it is reported that the silicate conversion coatings on HDG were featured by the favorable self-healing ability after immersion in sodium silicate solutions with SiO₂Na₄O molar ratio of 1.00 and 3.50 [27]. The silicate anions in the
coatings can migrate to the scratched area and form a new layer of conversion coating. Nevertheless, the preparation of water-resistant silicate coating requires a high-temperature drying process in order to increase the corrosion resistance [80]. It is difficult to apply such post-thermal treatment in terms of large metal bars of irregular shape. Min et al. [17] claimed that the addition of potassium methyl silicate into silicate conversion coating can improve the corrosion resistance without the need for thermal treatment.

1.2. Organic coatings

Organic coatings such as silane [19,81–87], acrylate [88] and epoxy resin [3,20] have emerged as promising alternatives. Among these, silane treatment is able to form a compact self-assembled silicon and oxygen network on the surface of metals. The resulting silane coatings are homogeneous and robust with superior corrosion resistance as physical barriers [89,90]. Chang et al. [81] fabricated silane coating on HDG steel by a sol-gel rolling coating method and achieved improved oxidation and corrosion resistance. However, there were some small defects like pinholes or cracks in the coating, which were prone to be attacked by the corrosion medium. Therefore, additives including oxide nanoparticles [19,82–85] and ions [86,87] were incorporated into the silane matrix to improve the barrier and self-healing effects. Liu et al. [91] prepared a superhydrophobic coating with contact angle of 151 ± 2° on Zn by immersion into a methanol solution of hydrolyzed 1H,1H,2H,2H-perfluorooyctyltrichlorosilane. The superhydrophobic coating displayed superior corrosion protection when immersed in 3% NaCl aqueous solution for 29 days.

A waterborne acrylic coating incorporated with titanium dioxide nanoparticles was fabricated on the surface of HDG steel by Lewis [88]. It was observed that addition of titanium oxide nanoparticles improved the protective effect of the coating due to its nature of hygroscopicity and high specific surface area.

Kartsonakis et al. [20] investigated the epoxy coating on HDG steel via dip coating process and demonstrated a promotional impact on the corrosion resistance as well as self-healing property. In addition, they also found that the addition of cerium molybdate nanocontainers loaded with corrosion inhibitor 2-mercaptobenzothiazole can further improve the corrosion resistance. Bajat et al. [3] claimed an increase in dry and wet adhesion strength of epoxy coating on HDG steel after pretreatment in hot air.

2. Current research status on biomedical Zn-based biodegradable metals

Commonly used metallic implants for biomedical applications are mostly made of stainless steel, titanium alloys and cobalt-chromium alloys. They possess excellent corrosion resistance and superior mechanical properties, maintaining a long-term mechanical stability in vivo. However, serious concerns still remain due to their non-biodegradability. Second surgery is necessary to remove the implants after the injured tissue healing, resulting in increased healthcare cost and further morbidity of patients [92,93]. In the past decades, biodegradable metals (BMs) have attracted much attention as temporary implants. In contrast to the traditional metallic biomaterials, BMs are mainly composed of essential metallic elements present in the human body in trace amounts. After fulfilling the mission of assisting tissue healing, BMs are able to gradually corrode in physiological environment with appropriate host response elicited by the degradation products [94]. In the design of biodegradable metallic implants, different parameters should be comprehensively considered to ensure their desired performance. Some specific design constraints and criteria for biodegradable implants based on the current research are displayed in Table 1 [35]. On account of these updated requirements, new challenges have been put forward in the development of BMs. Firstly, degradation products will be released into the surrounding physiological environment along with the proceeding of corrosion process (Fig. 2a).

Although the BMs mainly consist of human essential elements, the concentration of released degradation products should be optimized to ensure their biosafety. Secondly, the degradation behavior of BMs should match the evolution and kinetics of the tissue healing process. As for the cardiovascular applications, the wound healing process includes three characteristic stages: inflammation, granulation and remodeling (Fig. 2b) [96]. A complete degradation of stent is expected after the vessel remodeling phase, prior to which the mechanical performance of stent should maintain stable (Fig. 2c). Besides, the fractured bone healing proceeds in three distinct stages: inflammation, repair and remodeling phases (Fig. 2d and e). In terms of different implantation sites, the healing periods of the specific injured tissues are varied, coming up with customized requirements for the degradation period of BMs (Fig. 2f).

So far, there are mainly three kinds of widely-investigated BM systems, namely Mg-based BMs, Fe-based BMs and Zn-based BMs. For decades, Mg- and Fe-based metals and alloys have been the research hotspots in the field of BMs. However, the rapid degradation of Mg-based BMs in physiological environment hinders their further clinical applications. Given the uncontrollable corrosion behavior, excessive release of degradation products as well as premature loss of structural integrity can bring about undesired host response after the implantation of Mg-based BMs [101–103]. In addition, the mechanical properties of Mg-based BMs are not strong enough for the load-bearing applications [104]. In contrast, Fe-based BMs are characterized by the superior corrosion resistance and mechanical properties. Nonetheless, the slow corrosion may lead to a long-term existence of implant in vivo [105]. Meanwhile, the corrosion products of Fe are claimed to be stable and accumulate for a long time in vivo, impairing the integrity of arterial wall [106].

Recently, much interest has been focused on the research of Zn-based BMs. With the intermediate standard electrode potential between Mg (–0.23 V SHE) and Fe (–0.44 V SHE), Zn (–0.76 V SHE) has been put forward as a new research direction of BMs [107]. The preferable degradability of Zn-based BMs is expected to match the healing

| Table 1 | General design constraints and criteria for biodegradable metallic device applications (Reproduced with permissions from Ref. [95]). |
|---------|-------------------------------------------------------------------------------------------------|
| Criterion | Cardiovascular stent                                                                             | Orthopedic internal fixation device |
| Biocompatibility | Non-toxic, non-inflammatory, hypoallergenic                                                    | Non-toxic, non-inflammatory, hypoallergenic |
| No harmful release or retention of particulates |                                                  | No harmful release or retention of particulates |
| Promote endothelial cell attachment; discourage smooth muscle cell attachment |                                                  | Promote osteoblast and osteoclast attachment; avoid fibrous encapsulation |
| Mechanical integrity and resorption during service | Mechanical integrity: 3–6 months                                                               | Mechanical integrity: Plates and screws <6 months |
|                                                  | Full absorption in 1–2 years                                                                     | Full absorption in 1–2 years |
| Mechanical properties | Yield strength >200 MPa                                                                           | Yield strength >230 MPa |
| Tensile strength >300 MPa                                                                            | Tensile strength >300 MPa |
| Elongation of failure >15–18%                                                                         | Elongation to failure >15–18% |
| Elastic recoil on expansion <4%                                                                       | Elastic modulus approximates to that of cortical bone (10–20 GPa) |
| Corrosion behavior | Penetration rate < 20 µm year⁻¹                                                                 | Plates and screws (0.5 mm year⁻¹) |
| Hydrogen evolution < 10 µL cm⁻² ⋅ day⁻¹                                                               | Hydrogen evolution < 10 µL cm⁻² ⋅ day⁻¹ |
process of injured tissue, meeting the standards of clinical applications. Besides, the mechanical strength of Zn-based BMs is superior to that of Mg-based BMs, suggesting their potential applications at load-bearing sites [108]. Meanwhile, it is claimed that the primary cathodic reaction is supposed to be the oxygen reduction during the degradation of Zn in neutral physiological environment, avoiding the accumulation of hydrogen gas [109]. The maiden attempt of Zn-based BMs for biomedical applications can be traced to 2007 by Wang et al. [110]. They designed Zn-Mg alloys with Mg content ranging from 35 to 45 wt% and evaluated the mechanical properties and corrosion behavior in simulated body fluid (SBF) solution. Thereafter, the in vivo research of Zn-based BMs was firstly investigated in 2013 by implanting the pure Zn wires into the abdominal aorta of adult male Sprague-Dawley rats [111]. The in vivo outcomes indicated the promising corrosion behavior of Zn-based BMs. From then on, developing novel Zn-based BMs including Zn-based alloys and composites have burst forth.

2.1. The physiological functions of element Zn

Zn is one of the most abundant transition metal ions in the body, second only to iron. In terms of Zn distribution in human body, 85% is present in muscle and bone, 11% in the skin and liver and the residue in other tissues [112]. The major absorption and excretion routine of Zn take place in the intestine. The existence of Zn has been demonstrated in
more than 300 enzymes participating in their structure, catalytic and regulatory actions [113]. Zn plays a significant role in various biological functions [114] (Fig. 3a). It is indispensable for the growth of human and animals. Zn deficiency under different circumstance is directly associated with the retardation of bone growth, development and maintenance of bone health [115–117]. Both in vitro and in vivo studies have indicated that Zn can stimulate bone formation and mineralization [118,119]. Zn also interacts with vaso hormones related to bone growth [120]. Incorporation of Zn into biomaterials is able to improve the osteoblast differentiation by promoting the bone marker genes such as alkaline phosphatase, collagen type I, osteocalcin and osteopontin [116]. On the other hand, in comparison with other metal cations, Zn is unique as a potent inhibitor of osteoclastic bone resorption with an apparent inhibitory effect at a concentration as low as 10−14 M [121]. Besides, Zn plays an important role in the protection of coronary artery disease and cardiomyopathy [122]. Supplementation with Zn is able to improve the cardiac function and prevents further damage under the condition of ischemia and infarction [122]. Zn is important to maintain the normal endothelial integrity [123]. In addition, it can also stimulate the proliferation of endothelial cells by amplifying the endogenous basic fibroblast growth factor-dependent proliferation [124]. Zn is also associated with the development and integrity of the immune system. Zn has an important impact on the activity of some key immunity mediators consisting of enzymes, thymic peptides and cytokines [125]. Meanwhile, Zn is essential for intracellular regulation of lymphocyte apoptosis [125]. In addition, Zn participates in neurogenesis, synaptogenesis, neuronal growth and neurotransmission [126]. It is selectively stored in the presynaptic vesicles of specific neurons and released as neuro-modulator [126,127].

Although Zn is critical in plenty of physiological functions, excessive Zn exposure or intake can also result in detrimental impact on different organs in addition to insufficient Zn intake (Fig. 3b) [113]. Zn deficiency can result in a variety of pathological symptoms including growth failure, impaired parturition, hypotension et al. [122]. Many diseases are also accompanied by the lack of Zn such as gastrointestinal disorders, renal disease, sickle cell anemia and so on [113]. In contrast, excessive Zn can cause adverse consequence as well. Zn2+ is able to inhibit the electron transport in uncoupled mitochondria [128]. It is teratogenic or lethal for embryogenesis under the circumstance of excessive Zn intake [126]. Meanwhile, it is reported that Zn2+ has a biphasic effect on the cell viability, adhesion and proliferation. High concentration of Zn2+ would resulted in suppressive impact on cytocompatibility [129,130].

2.2. In vitro and in vivo degradation behavior and biocompatibility studies on Zn-based BMs for orthopedic applications

Recently, much attention has been paid to the applications of Zn-based alloys as orthopedic implant materials due to their preferable corrosion behavior in vivo as well as significant physiological functions of Zn ion [111,132]. The number of publications concerning Zn-based BMs for orthopedic applications since 2017 is 85 when analyzed via Web of Science database with the topics of Zn alloy and bone. Nonetheless, in view of the potential toxicity of Al, most commercial Zn alloys are not available for the biomedical applications [133,134]. Therefore, numerous researches have been carried out on the development of biomedical Zn-based alloys with the addition of human nutritional elements such as Ca, Mg, Sr, Mn, Li and so on [109]. However, the biosafety of Zn-based bulk materials still remains concerns due to the low inhibitory concentration threshold values of Zn2+ to cell and tissue [108]. The in vitro cytotoxicity and in vivo delayed osseointegration caused by the excessive release of Zn ions during degradation should be optimized for the further development of Zn-based BMs as orthopedic implants [135]. After implantation of Zn-based BMs in vivo, the corrosion products will gradually release into the surrounding physiological environment and react with the peripheral tissues and cells. The interactions between corrosion products and tissues at cellular and molecular level will influence a variety of physiological responses. The systemic investigation of in vitro and in vivo biocompatibility of Zn-based BMs have been conducted for orthopedic implants.

The in vitro biocompatibility of recently reported Zn-based BMs for orthopedic applications is summarized in Fig. 4. Up to now, a number of in vitro biocompatibility studies have implied that high concentration of the released Zn ions during the degradation process may cause cytotoxicity to osteoblast-like cells and fibroblasts. Su et al. [136] found a detrimental effect of 100% pure Zn extract on the cell proliferation and differentiation of MC3T3-E1 cell. Meanwhile, cells presented a round shape and limited spreading on the surface of pure Zn. Similar toxic effect of 100% extract of pure Zn has also been reported on MG-63 cells [137,138]. Genotoxicity refers to the damage on genetic materials such as DNA damage, gene mutation and impaired DNA repairment [139]. Murni et al. [140] claimed that the pure Zn extract will cause mild necrosis and significant DNA damage of NHöST cells. Alloying with other elements can alter the physiological response of Zn efficiently. Plenty of researches have reported that the addition of Mg can improve the biocompatibility of Zn. Murni et al. [140] pointed out that alloying with Mg can significantly alleviate the genotoxicity of Zn in Zn–3Mg alloy. In addition, Kubasch et al. [141] also confirmed that there was no significant DNA damage of U-2 OS cell line when cultured in the extract of Zn–0.8 Mg alloy. Similar positive influence of the addition of Mg on cell proliferation has also been reported on Zn-0.05 Mg [107] and Zn-0.5Al–xMg (x = 0.1, 0.3 and 0.5) alloys [142]. Besides, during the degradation of Zn–Mg alloy, the bone-like components such as skorpiolite and hydroxyapatite are supposed to stimulate the osseointegration [143]. In addition, the beneficial effects of Ca and Sr as alloying elements on cytocompatibility have also been proved [132].

So far, the in vivo biocompatibility studies of Zn-based BMs for orthopedic applications are relatively limited, as summarized in Fig. 5 and Table 2. It is revealed that excessive release of Zn ions resulted in the poor osseointegration in vivo (Figure 5a and 5d-f). Yang et al. [146] implanted the pure Zn into the rat femur condyle. A serious fibrous tissue encapsulation was found for pure Zn, resulting in the lack of direct bonding between bone and implant (Fig. 5e). The delayed osseointegration of pure Zn is claimed to be attributed to the local high Zn ion concentration. In consistence with the observations in vitro, the in vivo results confirmed that alloying with appropriate elements such as Mg, Ca and Sr can effectively improve the biocompatibility (Fig. 5a). Li et al. [132] indicated that Zn–1Mg, Zn–1Ca and Zn–1Sr alloys were able to improve the new bone formation after two months of implantation (Fig. 5b). Meanwhile, compared with Mg, the promoting effects of Ca and Sr were superior with a ranking of Zn–1Sr > Zn–1Ca > Zn–1Mg. A favorable in vivo osteogenesis was found around Zn-0.05 Mg alloy as well (Fig. 5e) [107]. As for the ternary alloys, the addition of any two of these elements also confirmed better cytocompatibility with Zn–1Ca–1Sr ranking the best, which is in agreement with the finding in binary alloys [152]. In addition, the fabrication of metal matrix composite is another efficient way to improve the biocompatibility of Zn. Yang et al. [146] fabricated Zn-hydroxyapatite biocomposite by spark plasma sintering and achieved an increased corrosion rate with better cytocompatibility. However, although superior new bone formation was found compared with pure Zn, the lack of direct bone bonding of Zn-hydroxyapatite biocomposite in vivo suggested delayed osseointegration (Fig. 5f). In addition, the incorporation of Mg into Zn by spark plasma sintering exhibited accelerated corrosion behavior and better osteointegration with sacrificial Mg-rich anode as shown in Fig. 5g [145]. Biocompatibility is the ability of a material to perform its desired functions in accordance to a medical therapy with the most appropriate host response in that specific situation, instead of causing any adverse local or systemic effects [158]. In comparison with Fe and Mg, the tolerance value of organism to Zn is much lower. It is noted that the recommended daily intake (RDI) value for Zn (6.5–15 mg) is similar to that of Fe (10–20 mg), but much lower than that of Mg (375–700 mg).
In addition, the serum concentration of Zn is 0.012 mmol L⁻¹, which is similar to that of Fe (0.013–0.031 mmol L⁻¹), but much lower than that of Mg (0.7–1.0 mmol L⁻¹) [108]. In vitro cytocompatibility assay also demonstrated that the viabilities of MC3T3-E1 and L929 cells were more sensitive to the concentration of Zn ions in contrast with that of Mg and Fe ions. Yamamoto et al. [159] studied the cytotoxicity of 43 metal salts to murine fibroblasts and osteoblastic cells. The IC₅₀ values of MC3T3-E1 cell and L929 cell for Mg²⁺ (3.28 × 10⁻⁴ mol L⁻¹) were much higher than those of Zn²⁺ (9 × 10⁻⁵ mol L⁻¹ and 9.28 × 10⁻⁵ mol L⁻¹), demonstrating a better cytocompatibility of Fe³⁺. Note that the IC₅₀ value of Mg²⁺ is seldom studied, Mg salt is indispensably required to be provided for cell culture. The amount of Mg²⁺ in DMEM is approximately 8.13 × 10⁻⁴ mol L⁻¹, which is obviously higher than the IC₅₀ values of Zn²⁺ [160]. The median lethal dose (LD₅₀) is generally utilized to evaluate the in vivo biocompatibility and long-term chronic toxicity of metallic elements. The LD₅₀ values of the chloride of element Zn is 350 mg kg⁻¹, far below the values of the chloride of Fe (1300 mg kg⁻¹) and Mg (5000 mg kg⁻¹) [108]. Hence, although Zn-based BMs stand out with superior corrosion behavior, more attention should be focused on their biosafety in consideration of the threshold concentration to cause biotoxicity.

### 2.3. In vitro and in vivo degradation behavior and biocompatibility studies on Zn-based BMs for cardiovascular applications

In comparison with the traditional permanent metallic stents, biodegradable metallic stents are bioactive and only provide provisional support until vessel healing. Therefore, some long-term clinical issues corresponding to the persistent existence of stents, including the chronic inflammation, stent thrombosis, in-stent restenosis and prolonged anti-platelet therapy, can be avoided [161,162]. The first attempt of application of Zn-based BMs in cardiovascular environment can be traced to 2013. Bowen et al. [111] implanted pure Zn wires into the abdominal aorta of adult male Sprague-Dawley rats up to six months. It was claimed pure Zn can maintain mechanical stability during the initial four months and, subsequently, it showed accelerated disintegration, demonstrating the near-ideal biocorrosion behavior for cardiovascular stent applications. From then on, numerous researches have been focused on the development of Zn-based BMs for cardiovascular applications. There are 51 publications regarding Zn-based BMs for cardiovascular applications since 2017 when analyzed via Web of Science database with the topics of Zn alloy and stent. Nonetheless, the mechanical properties of pure Zn are not strong enough for cardiovascular stent, hampering its further applications. The tensile strength and elongation of as-cast pure Zn are only 20 MPa and 0.3%, far below the clinical requirements as shown in Table 1 [163]. Therefore, diverse improvement methods including alloying and thermomechanical treatments have been adopted to realize the applications of Zn-based BMs in cardiovascular field. As summarized in Table 3, tailoring the composition and microstructure will lead to changes in the mechanical properties, corrosion behavior and biocompatibility of Zn-based BMs. Alloying with metallic elements such as Li, Mg, Ca, Sr, Mn, Cu and Ag can significantly improve the mechanical performance of Zn-based BMs.

The reported in vivo researches of Zn-based BMs for cardiovascular applications are displayed in Fig. 6 and Table 4. Yang et al. [164] implanted pure Zn stents into the abdominal aortas of adult Japanese rabbits (Fig. 6a). It was found that there was no phenomenon of severe inflammatory response, platelet aggregation, thrombosis formation and intimal hyperplasia after the implantation of pure Zn stents. The mechanical integrity of stents maintained stable for 6 months, while the stent volume decreased by 41.75 ± 29.72% after 12 months’ implantation. Zhou et al. [165] implanted Zn-0.8Cu alloy stents into the porcine coronary arteries for 24 months and demonstrated the absence of inflammation and thrombosis formation (Fig. 6b). Later on, Zn-3Ag alloy stents were fabricated and implanted into the iliofemoral arteries of juvenile domestic pigs by Hehrlein et al. [166]. Excellent vascular healing was observed with no signs of thrombosis or vascular occlusion (Fig. 6c). Jin et al. [167] implanted Zn-xMg (x = 0.002, 0.005 and 0.08) alloy wires into the abdominal aorta of adult male Sprague-Dawley rats (Fig. 6d). It was claimed that a mild inflammation and intimal activation...
can be observed. Besides, it seems that the biocompatibility became worse with the increase in Mg content, which might be attributed to the formation of intermetallics. Zhao et al. [168] implanted Zn-0.1Li alloy wires into the abdominal aorta of rats and found that Zn-0.1Li alloy system exhibited a moderate inflammatory response without obstructive neointima (Fig. 6e). Zn-xAl (x = 1, 3 and 5) alloy stripes were implanted into the wall of the abdominal aorta of adult Sprague-Dawley rats by Bowen et al. [169]. It was demonstrated that a moderate inflammatory response without obstructive neointima (Fig. 6e).
response without any signs of necrosis took place after implantation (Fig. 6f).

3. Surface modification of Zn-based BMs for biomedical applications

3.1. Surface modification of Zn-based BMs for orthopedic applications

The interactions between the tissues and implants are directly associated with the surface characteristics of the implants. Surface modification is one of the most efficient ways to improve the surface properties of implanted materials and endow them with new functions. In comparison with alloying or compositing, surface modification only alters the surface characteristics of Zn-based BMs, maintaining the original performance of bulk materials. So far, the primary aim of the limited reports on the surface modification of biodegradable Zn-based BMs for orthopedic applications is to construct a temporary surface featured by the proper corrosion behavior and superior biocompatibility. The development and representative surface morphologies of Zn-based BMs after different surface modifications for orthopedic applications are summarized in Table 5 and Fig. 7.

(1) Phosphate conversion coating

Zinc phosphate has been put forward as versatile material for biomedical applications [195,196]. It can stimulate the adsorption of Ca\(^{2+}\) ascribed to the existence of PO\(_4^{3-}\). Meanwhile, it is also reported that zinc phosphate has a stimulative effect on the growth of hydroxyapatite under the condition of immersion in simulated body fluid [197]. Su et al. [136] investigated the zinc phosphate coating fabricated by immersing pure Zn discs in the mixed solution of Zn(NO\(_3\))\(_2\) and H\(_2\)PO\(_4\). They found that the zinc phosphate coating improved the cell viability, adhesion and proliferation of pre-osteoblasts while suppressed the adhesion of E. coli, which is attributed to the decreased Zn ions release and micro/nano surface topography.

(2) Biomimetic deposition

Generally, biomimetic process proceeds when the samples are immersed in aqueous solutions of supersaturated calcium and phosphate, resulting in the formation of calcium phosphate coating on the surface [198]. Jablonska et al. [155] pretreated the Zn-1.5 Mg alloy in the simulated body fluid at 37 °C for 14 days. Consequently, a layer of protective film, abundant in calcium phosphate, was generated on the surface. The resulting coating led to improved corrosion resistance as well as better cell viability and adhesion of U-2 OS cells.

(3) Organic and polymer coating

The biodegradable organic and polymer coatings can protect the...
Table 3
Summary of the mechanical properties, in vitro biodegradability and biocompatibility of the reported Zn-based BMs for cardiovascular applications.

| Material Working history | Mechanical properties | In vitro corrosion | In vitro cytocompatibility | Ref. |
|-------------------------|-----------------------|--------------------|----------------------------|------|
|                         | Ultimate tensile strength (MPa) | Tensile yield strength (MPa) | Elongation (%) | Corrosion medium | Electrochemical test (mm/year) | Immersion test (mm/year) | Cell line | Cell viability |
|                         | ( ultimate  | ultimate  | (ultimate  | (ultimate  | (ultimate  | (ultimate  | | |
| Zn (99.99%) Cast       | 18.25 ± 2.99          | 10.14 ± 2.32       | 0.32 ± 0.08  | Hank’s solution | −0.13 | −0.08 | Human umbilical vein endothelial cell (ECV304) | −88% (5d, 100% extract) | [132] |
| Zn (99.99%) Rolled     | −48.7                 | −30.0              | −5.6         | Hank’s solution | −0.13 | −0.07 | Rodent vascular smooth muscle cell (VSMC) | −72% (5d, 100% extract) | [132] |
| Zn (99.99%) Extruded   | −63.7                 | −34.2              | −3.5         | Hank’s modified solution | −0.13 | −0.07 | Human umbilical vein endothelial cell (ECV304) | −88% (5d, 100% extract) | [132] |
| Zn (99.99%) Extruded   | 111 ± 4.5             | 51 ± 3.7           | 60 ± 5.9     | Hank’s modified solution | 0.56 ± 0.18 | | Human umbilical vein endothelial cell (EA.hy926) | −20% (5d, 100% extract) | [171] |
|                      | Zn (99.9+%)           |                      |              |                  |                  |                  | Human umbilical vein endothelial cell (EA.hy926) | −30% (5d, 100% extract) | [172] |
| Zn Rolled             | −142                  | −111               | 36 ± 2       |                  |                  |                  | Human umbilical vein endothelial cell (HUVEC) | −108 (3d, 100% extract) | [173] |
| Zn Selective laser melting |                  |                  |              |                  |                  |                  | Human umbilical vein endothelial cell (ECV304) | −101% (5d, 100% extract) | [174] |
| Zn–0.002Mg Extruded   | 63 ± 9                | 34 ± 4             | 17 ± 3       |                  |                  |                  | Human umbilical vein endothelial cell (HUVEC) | −108 (3d, 100% extract) | [175] |
| Zn–0.005Mg Extruded   | 202 ± 60              | 93 ± 1             | 28 ± 2       |                  |                  |                  | Human umbilical vein endothelial cell (ECV304) | −101% (5d, 100% extract) | [176] |
| Zn–0.08Mg Extruded    | 339 ± 42              | 221 ± 14           | 40 ± 3       |                  |                  |                  | Human umbilical vein endothelial cell (ECV304) | −101% (5d, 100% extract) | [177] |
| Zn–0.15Mg Extruded    | 250 ± 9.2             | 114 ± 7.7          | 22 ± 4.0     |                  |                  |                  | Human umbilical vein endothelial cell (ECV304) | −70% (5d, 100% extract) | [178] |
| Zn–0.02Mg Extruded    | 231.5 ± 3.56          | 188.67 ± 6.19      | 31.08 ± 3.41 |                  | 0.093 ± 0.006    |                  | Human umbilical vein endothelial cell (HUVEC) | −108 (3d, 100% extract) | [179] |
| Zn–0.05Mg Extruded    | 227 ± 5               | 197 ± 4            | 34 ± 3       |                  | −0.16 | −0.08 | Human umbilical vein endothelial cell (EA.hy926) | −20% (5d, 100% extract) | [180] |
| Zn–0.1Mg Cast         | 184.84 ± 20.91        | 127.98 ± 10.72     | 1.82 ± 0.23  |                  |                  |                  | Human umbilical vein endothelial cell (ECV304) | −101% (5d, 100% extract) | [181] |
| Zn–0.1Mg Rolled       | −235.5                | −187.9             | 11.8         |                  | −0.15 | −0.08 | Rodent vascular smooth muscle cell (VSMC) | −70% (5d, 100% extract) | [182] |
| Zn–0.1Mg Extruded     | −266.3                | −205.4             | 8.4          |                  | −0.17 | −0.08 | Human umbilical vein endothelial cell (ECV304) | −101% (5d, 100% extract) | [183] |
| Zn–1Mg Cast           | 164.57 ± 13.92        | 119.12 ± 7.01      | 2.10 ± 0.23  |                  |                  |                  | Human umbilical vein endothelial cell (ECV304) | −100% (5d, 100% extract) | [184] |
| Zn–1Mg Rolled         | −251.8                | −204.9             | −12.6        |                  | −0.16 | −0.09 | Rodent vascular smooth muscle cell (VSMC) | −70% (5d, 100% extract) | [185] |
| Zn–1Mg Extruded       | −242.4                | −201.5             | −7.6         |                  | −0.17 | −0.10 | Human umbilical vein endothelial cell (ECV304) | −102% (5d, 100% extract) | [186] |
| Zn–1Sr Cast           | 171.40 ± 14.13        | 120.21 ± 6.08      | 2.03 ± 0.22  |                  |                  |                  | Rodent vascular smooth muscle cell (VSMC) | −73% (5d, 100% extract) | [187] |
| Zn–1Sr Rolled         | −227                 | −187.4             | −19.7        |                  | −0.17 | −0.10 | Human umbilical vein endothelial cell (ECV304) | −102% (5d, 100% extract) | [188] |
| Zn–1Sr Extruded       | −265.3                | −217.4             | −10.6        |                  |                  |                  | Rodent vascular smooth muscle cell (VSMC) | −73% (5d, 100% extract) | [189] |

(continued on next page)
| Material     | Working history | Ultimate tensile strength (MPa) | Tensile yield strength (MPa) | Elongation (%) | In vitro corrosion | In vitro cytocompatibility | Ref. |
|--------------|-----------------|--------------------------------|-----------------------------|----------------|-------------------|----------------------------|------|
|              |                 |                                |                             |                |                   |                            |      |
| Zn–2Li       | Rolled          | −364                           | −238                        | −14.3          | Modified SBF solution     | 0.06                        | [176]|
| Zn–4Li       | Rolled          | −440                           | −423                        | −13.7          | Modified SBF solution     | 0.06                        | [176]|
| Zn–6Li       | Rolled          | −562                           | −473                        | −2.3           | Modified SBF solution     | 0.05                        | [176]|
| Zn–1Cu       | Extruded        | 186.3 ± 0.5                    | 148.7 ± 0.5                 | 21.0 ± 4.4     | c-SBF solution          | −0.033                      |      |
| Zn–2Cu       | Extruded        | 240.0 ± 1.4                    | 199.7 ± 4.2                 | 46.8 ± 1.4     | c-SBF solution          | −0.027                      |      |
| Zn–3Cu       | Extruded        | 257.0 ± 0.81                   | 213.7 ± 1.2                 | 47.2 ± 1.0     | c-SBF solution          | −0.030                      |      |
| Zn–3Cu       | Extruded        | 288 ± 4.03                     | −288                        | 45.9 ± 3.33    | SBF solution            | 0.0852                      |      |
| Zn–4Cu       | Extruded        | 270 ± 10                       | 250 ± 10                    | 51 ± 2         | Hank’s solution         | 0.00941 ± 0.00134          |      |
| Zn–0.2Mn     | Extruded        | 220                            | 132                         | 48             |                   |                            |      |
| Zn–0.6Mn     | Extruded        | 182                            | 118                         | 91             |                   |                            |      |
| Zn–2.5Ag     | Extruded        | −203                           | −147                        | 35             | Hank’s modified solution| 0.137 ± 0.021               | 0.079 ± 0.007                  | [181]|
| Zn–3Ag       | Extruded        | 240–260                        | 130–145                     | 70–135         | Hank’s modified solution| 0.144 ± 0.007               | 0.081 ± 0.001                  | [182]|
| Zn–5.0Ag     | Extruded        | −253                           | −208                        | 77             | Hank’s modified solution| 0.147 ± 0.018               | 0.084 ± 0.005                  | [182]|
| Zn–7.0Ag     | Extruded        | −287                           | −236                        | 32             |                    |                            |      |
| Zn–0.5Al     | Extruded        | 203 ± 9.6                      | 119 ± 2.3                   | 33 ± 1.2       | Hank’s modified solution| −0.14                      | −0.08                        | [170]|
| Zn–1Al       | Extruded        | 223 ± 4.3                      | 134 ± 5.8                   | 24 ± 4.2       | Hank’s modified solution| −0.14                      | −0.08                        | [170]|
| Zn–1Al       | Rolled          | −238                           | −197                        | −24            |                   |                            |      |
| Zn–3Al       | Rolled          | −224                           | −203                        | −31            |                   |                            |      |
| Zn–5Al       | Rolled          | −308                           | −240                        | −16            |                   |                            |      |
| Zn–0.02Mg– 0.02Cu | Extruded | 262.25 ± 5.02 | 216.29 ± 3.27 | 27.4 ± 2.21 | Hank’s solution 0.079 ± 0.004 | 0.047 ± 0.005 | [183]|
| Zn–0.02Mg– 0.02Cu | Extruded | 262.25 ± 5.02 | 216.29 ± 3.27 | 27.4 ± 2.21 | Hank’s solution 0.079 ± 0.004 | 0.047 ± 0.005 | [183]|
| Zn–3Cu–0.5Fe | Extruded        | 284 ± 1.63                     | −231                        | 32.7 ± 4.17    | SBF solution           | 0.1045                      | 0.0643 ± 0.00403             | [184]|
| Zn–3Ca–1Fe   | Extruded        | 272 ± 7.48                     | −219                        | 19.6 ± 1.36    | SBF solution           | 0.1301                      | 0.0689 ± 0.00734            | [185]|
| Zn–1.5Cu–1.5Ag | Cast     | 77.2 ± 2.25                   | 75.3 ± 2.49                 | 0.54 ± 0.09    |                   |                            |      |
| Zn–1.5Cu–1.5Ag | Extruded | 220.3 ± 1.70                  | 162.0 ± 2.94                | 44.13 ± 1.09   | c-SBF solution        | 0.019 ± 0.00086            | 0.0486 ± 0.00414            | [185]|
|               |                 |                                |                             |                |                   |                            |      |

Table 3 (continued)
| Material                  | Working history  | Ultimate tensile strength (MPa) | Tensile yield strength (MPa) | Elongation (%) | In vitro corrosion | In vitro cytocompatibility | Ref.|
|---------------------------|------------------|--------------------------------|-----------------------------|----------------|---------------------|----------------------------|-----|
| Zn–3Cu–0.1Mg             | Extruded         | −418                           | −404                        | −2.1           | Hank’s solution     | Human endothelium-derived cell (EA. hy926) | −74% (5d, 100% extract) |
| Zn–3Cu–0.5Mg             | Extruded         | −441                           | −428                        | −1.0           | Hank’s solution     | Human endothelium-derived cell (EA. hy926) | −88% (5d, 100% extract) |
| Zn–3Cu–1.0Mg             | Extruded         | 274 ± 5                        | 230 ± 3                     | 41 ± 1         |                    | Human endothelium-derived cell (EA. hy926) | −92% (5d, 100% extract) |
| Zn–0.1Mn–0.05Mg          | Rolled/naturally aged | 312 ± 2                      | 241 ± 5                     | 44 ± 2         |                    |                            | [174]|
| Zn–0.5Cu–0.05Mg          | Rolled/naturally aged | 120.1 ± 3.2                   | 113.2 ± 0.2                 | 0.4 ± 0.1      |                    |                            | [174]|
| Zn–0.75Mn–0.40Cu         | Cast              | 277.5 ± 3.7                    | 195.5 ± 10.7                | 29.6 ± 3.8     | SBF solution       |                            | [187]|
| Zn–0.75Mn–0.40Cu         | Roll              | 83.9 ± 0.4                     | 76.7 ± 0.3                  | 0.3 ± 0.1      |                    |                            | [187]|
| Zn–0.35Mn–0.41Cu         | Cast              | 292.4 ± 3.4                    | 198.4 ± 6.7                 | 0.098 ± 0.005  | SBF solution       |                            | [187]|

Fig. 6. Representative in vivo biocompatibility of Zn-based cardiovascular implants in the literature: (a) hematoxylin-eosin (H&E) stained sections of abdominal aorta after 1, 3, 6 and 12 months’ implantation of pure Zn stents. (Reproduced with permissions from Ref. [164]). (b) H&E-stained cross-sections after implantation of Zn–0.8Cu alloy stents in the porcine coronary arteries for 1, 3, 9, 24 months. (Reproduced with permissions from Ref. [165]). (c) Histologic images of representative cross-sections of porcine iliofemoral arteries stented with a Zn–3Ag bioreabsorbable vascular stent after 3 and 6 months. (Reproduced with permissions from Ref. [166]). (d) H&E staining of 6-months implanted Zn-0.002 Mg, Zn-0.005 Mg, and Zn-0.08 Mg alloy wires through the arterial lumen at different magnifications. 2nd and 3rd rows correspond to green and yellow asterisks respectively at high magnifications. L denotes the luminal opening. (Reproduced with permissions from Ref. [167]). (e) H&E staining of Zn–0.1Li alloy wires after 11 months’ implantation in the abdominal aorta of Sprague Dawley rat. Low magnification images show two subsequent areas selected for high magnification. “L” is the luminal opening of the artery. (Reproduced with permissions from Ref. [168]). (f) H&E staining of Zn–xAl alloy (x = 1, 3 and 5) strips after implantation in the wall of the abdominal aorta of adult Sprague-Dawley rats for 1.5–6 months. Black triangles mark the interface between the native adventitial tissue and corroding product/remodeled tissue. (Reproduced with permissions from Ref. [169]). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
In vivo biocorrosion and biocompatibility properties of biodegradable Zn-based BMs for cardiovascular applications.

| Material | Implant shape | Animal model | Implant site | In vivo corrosion rate (mm/year) | Period | Thrombosis | Inflammatory response | Reference |
|----------|---------------|--------------|--------------|---------------------------------|--------|------------|-----------------------|-----------|
| Pure Zn | Stent         | Adult male Sprague Dawley rat | Abdominal aorta | 0.027 at 4.5 months and ~0.050 at 11 months | 11 months | - | - | [164] |
| Pure Zn | Wire          | Male young CD IGS rat | Abdominal aorta | 0.032 at 4.5 months and ~0.023 at 11 months | 11 months | - | - | [165] |
| Zn-0.002Mg | Wire | Male young CD IGS rat | Abdominal aorta | ~0.015 at 4.5 months and ~0.023 at 11 months | 11 months | - | - | [166] |
| Zn-0.08Mg | Wire | Adult male Sprague-Dawley rat | Left anterior descending artery | ~0.016 at 3 months | 6 months and 0.040 at 12 months | - | - | [167] |
| Zn-0.1Li | Wire | Female New Zealand white rabbit | Abdominal aorta | ~0.019 at 9 months and ~0.046 at 12 months | 12 months | - | - | [168] |
| Zn-0.02Mg | Stent | Adult male Sprague-Dawley rat | Abdominal aorta | ~0.025 at 3–6 months and 0.040 at 12 months | 12 months | - | - | [169] |
| Zn-3Li | Wire | Rat | Abdominal aorta | - | 6 months | - | - | [170] |
| Zn-2Ag | Stent | Juvenile domestic swine | Left common carotid artery | - | 12 months | - | - | [171] |
| Zn-0.013Li | Wire | New Zealand white rabbit | Left common carotid artery | - | 3 months and 0.040 at 12 months | - | - | [172] |

Note: Positive; Negative; NA: Not available.

(4) Electrochemical method

Anodic oxidation (ANO) involves a process of electrolytic passivation which can grow a stable and uniform oxide film with controllable and desired thickness on the anode surface. It is reported that various nanosstructures can be constructed on the surface of Zn after anod oxidation including nanowires [202], nanotrips [203], nanosheets [204], nanotubes [205] and so on. Gilani et al. [206] constructed ZnO micro/nano hole array and nanoparticle array on Zn foil by anod oxidation and demonstrated superior antibacterial property against both Gram-negative E. coli and Gram-positive S. aureus. Besides, Lyu et al. [207] fabricated dexamethasone-laden ZnO nanotube on Zn substrate by anod oxidation followed by silk fibroin/graphene self-assembly. They found that this composite coating enhanced the biocompatibility and antibacterial property due to the synergistic release of Zn ions and drug during degradation.

In contrast with anodic oxidation, microarc oxidation (MAO) treat ment proceed under a high-voltage discharge. Homogeneously distributed micro pores are formed on the surface during the microarc oxidation process when the molten oxide and gas bubble are ejected through the microarc discharge channel. MAO technology has been widely applied to construct porous, rough and adherent oxide coating on the surface of metals such as magnesium [208,209], aluminum [210, 211] and titanium [212]. Meanwhile, calcium, phosphorus or other ele ments can be incorporated into the oxide layer by adding corres ponding electrolyte ingredients, improving the osteogenesis and biocompatibility [213]. Yuan et al. [137] fabricated microarc oxidation coating incorporated with CaP compound on the surface of pure Zn. Instead of improved corrosion resistance that have been found on Mg alloys, they found that MAO coating accelerated the corrosion rate of pure Zn due to anabatic chemical dissolution and galvanic corrosion between the coating and substrate.

(5) Atomic layer deposition

Atomic layer deposition (ALD) has been put forward as a promising approach of depositing nanofilm in a variety of applications. ALD shows advantages of precise control over material thickness and composition at angstrom level [214]. In addition, a layer of extremely smooth and conformal film can be generated on both flat surface and high aspect ratio structures after ALD treatment [215]. In terms of biomedical applications, different metallic oxide films have been constructed on the surface of Mg-based BMs via ALD as coating materials to improve their corrosion resistance and biocompatibility [216]. Recently, Yuan et al. [135] prepared a layer of homogeneous ZrO2 film with the film thickness ranging from 40 nm to 120 nm on the surface of Zn–Li alloy by means of ALD. They found a beneficial effect of the ZrO2 nanofilm on the corrosion resistance of Zn–Li alloy, accompanied by a less release of Zn2+ in corrosion media. Meanwhile, better in vitro cell adhesion and proliferation as well as in vivo osseointegration were demonstrated after ALD treatment.

(6) Magnetron sputtering

Magnetron sputtering has been widely applied to deposit high-quality functional coatings on the surface of diverse materials [217, 218]. Peng et al. [193] produced diamond-like carbon (DLC) film on the substrate from the attack of aggressive corrosion media in physiological environment, which has been widely applied in the corrosion protection of BMs [199–201]. Besides, the ability of drug delivery and functioning with other biomolecules also render them promising alternatives. Collagen coating has been proposed to modify the surface of pure Zn via dip-coating by Su et al. [136]. The collagen coating exhibited a favorable impact on the corrosion resistance and cytocompatibility for pre-osteoblasts and endothelial cells.
Table 5
Summary of different surface modification methods of Zn-based BMs for orthopedic applications.

| Surface modification method | Substrate | Techniques and modified layer | Main layer structure | Layer thickness | In vitro corrosion rate (mm/y) | In vitro biocompatibility | In vivo biocompatibility | Ref. |
|-----------------------------|-----------|-------------------------------|---------------------|----------------|-------------------------------|--------------------------|--------------------------|------|
| Chemical method             | Pure Zn (99.99+%) | Phosphate conversion coating | Immersing in 0.07 M Zn(NO₃)₂ and 0.15 M H₃PO₄ solution, pH 2-3 | Zinc phosphate 5-6 μm | Hank’s solution 0.004 ± 0.001 | i. Murine calvarial pre-osteoblast (MC3T3-E1) ii. Human endothelial cell (EA.hy926) Improved cell adhesion, proliferation and differentiation | Both platelets adhesion and hemolysis tests showed good hemocompatibility with no sign of thrombogenicity | [136] |
|                             | Pure Zn (99.99%) | Immersion in the mix solution of 0.07 M Zn(NO₃)₂, 0.15 M H₃PO₄ and 1 g/L graphene oxide, pH 2.5 | Graphene oxide (GO)-containing zinc phosphate 4.65 ± 0.45 μm | Hank’s solution 0.0685 ± 0.003 | | | | [190] |
| Organic and polymer coating | Pure Zn (99.99%) | Dip-coating in the 1 mg/ml rat tail type I collagen solution for 20 min at room temperature | Rat tail type I collagen 2.5 μm | Hank’s solution 0.085 ± 0.009 | i. Murine calvarial pre-osteoblast (MC3T3-E1) ii. Human endothelial cell (EA.hy926) Improved cell proliferation and differentiation | | | [136] |
|                            | Zn-1.5Mg | Immersing in SBF for two weeks | Calcium phosphate | MEM cultivation medium with 5% fetal bovine serum | 0.019 ± 0.011 (mg cm⁻² day⁻¹, with CO₂ atmosphere); 0.004 ± 0.002 (mg cm⁻² day⁻¹, without CO₂ atmosphere); | i. Murine fibroblast (L929) ii. Human osteosarcoma cell (U-2 OS) Improved cell viability Improved cell adhesion number with more spreading | | [155] |
| Biomimetic deposition       | Zn-3Cu-1Mg | Immersing in Ca(H₂PO₄)·H₂O, sodium nitrate and hydrogen peroxide mixture solution for 1d at 20 °C | CaHPO₄·2H₂O | | Bone marrow mesenchymal stem cell (BMSC) Improved cell proliferation, osteogenic differentiation and calcium deposition | | | [191] |
| Stabilization treatment     | Zn-1Mg | Immersing in Dulbecco’s Modified Eagle’s Medium for 1 day under a humidified atmosphere with 5% CO₂ at 37 °C | ZnO and Zn (OH)₂ | | Murine mesenchymal stem cell (MSC) Improved cell adhesion and proliferation | | | [192] |
|                            | Zn-1Mg-0.5Ca | | | | Improved cell adhesion and proliferation | | | |
| Electrochemical method      | Pure Zn (99.999%) | Microarc oxidation | 400 V, 3 min, electrolyte: 2.5 g/L sodium hydroxide and 0.02 mol/L calcium | Zn and amorphous Ca₅(PO₄)₂ −25 μm | Hank’s solution 1.361 ± 0.124 | Human osteoblast-like cell (MG63) Decreased cell proliferation and improved cell adhesion. | | [137] |

(continued on next page)
| Surface modification method | Substrate | Techniques and modified layer | Main layer structure | Layer thickness | In vitro corrosion rate (mm/y) | In vitro biocompatibility | In vivo Biocompatibility | Ref. |
|-----------------------------|-----------|--------------------------------|----------------------|----------------|------------------------------|--------------------------|--------------------------|------|
| Physical method             | Atomic layer deposition | Zn-0.1Li | Glycerophosphate hydrate dissolved in deionized water | Amorphous ZrO₂ | 120 nm | Hank’s solution | 0.054 ± 0.014 | Improved cell adhesion and proliferation | Improved in vivo osseointegration | [135] |
|                             | Magnetron sputtering | Pure Zn (≥99.995%) | Tetrakis (dimethylamino) zirconium (TDMAZ) as Zr precursor (heated to 120 °C), deionized water as O precursor (heated to 35 °C), 500 deposition cycles | Diamond-like carbon | 100 nm | DMEM/F-12 | 0.035 | Decreased cell proliferation | Decreased cell proliferation | [193] |
| Mechanical method           | Sandblasting | Pure Zn | Abrasive: Al₂O₃ (250 μm particle size), distance between jet and sample surface: 10 mm, pressure: 2 bar, time: 20 s | | | | | | Human osteosarcoma cell (Saos-2) | Decreased cell proliferation | [194] |
surface of pure Zn. They found that the DLC film accelerated the corrosion of substrate, which is possibly attributed to the galvanic corrosion between the film and Zn substrate. Meanwhile, a decrease in cytocompatibility was also demonstrated for the DLC-coated Zn.

(7) Sandblasting

Sandblasting is a simple and universal approach to increase the surface roughness by forcing small grits of specific shape and size across the surface of materials [219,220]. In addition, it is also claimed that sandblasting can improve the biocompatibility of biomaterials by adjusting the surface roughness and morphology. Li et al. [194] investigated the effects of sandblasting surface treatment on degradation

Fig. 7. The representative surface morphologies of the coatings prepared by different surface modification methods of Zn-based BMs for orthopedic application: (a) Microarc oxidation coating. (Reproduced with permissions from Ref. [137]). (b) Phosphate conversion coating. (Reproduced with permissions from Ref. [136]). (c) Biomimetic deposition. (Reproduced with permissions from Ref. [155]). (d) Collagen coating. (Reproduced with permissions from Ref. [136]). (e) Atomic layer deposition of ZrO$_2$ coating. (Reproduced with permissions from Ref. [135]).

Fig. 8. The surface morphologies of the coatings prepared by different surface modification methods of Zn-based BMs for cardiovascular applications: (a) Anodization coating. (Reproduced with permissions from Ref. [223]). (b) Electropolished surface. (Reproduced with permissions from Ref. [223]). (c) Air oxidation coating. (Reproduced with permissions from Ref. [223]). (d) PLLA coating. (Reproduced with permissions from Ref. [223]).
behavior and biocompatibility of pure Zn, Zn–4Ag and Zn–2Ag–1.8Au–0.2 V. They found that sandblasting increased the corrosion rates of Zn and Zn alloys, while an adverse impact of sandblasting on cytocompatibility was also observed.

### 3.2. Surface modification of Zn-based BMs for cardiovascular applications

So far, there is only limited research on the surface modification of Zn-based BMs aimed at cardiovascular applications as summarized in Fig. 8 and Table 6. Shearier et al. [221] constructed dopamine coating and dopamine/gelatin composite coating on the surface of pure Zn foils. It was demonstrated that both coatings had a beneficial effect on the cell viability of human dermal fibroblasts, human aortic smooth muscle cells and human aortic endothelial cells. Shomali et al. [222] reported the preparation of MPS/PLLA coating on the surface of pure Zn wires by dip-coating. Although an improved corrosion resistance was achieved after surface modification, the biocompatibility was reduced with increased cytotoxicity and neointimal hyperplasia, which can be caused by the toxic and acid degradation by-products of PLLA. Drellich et al. [223] constructed oxide films of diverse thickness and structure on pure Zn wires by oxidation, electropolishing and anodization, and studied the impact of oxide films on the corrosion behavior. It is claimed that the defects/cracks in the oxide film will accelerate the biocorrosion of Zn-based BMs as local corrosion sites. MAO coating, which is mainly composed of ZnO and Zn2SiO4, was prepared on Zn–1Mg alloy by Sheng et al. [224]. A beneficial effect of MAO treatment on the corrosion resistance was observed. Besides, they also demonstrated improved

### Table 6

Summary of different surface modification methods of biodegradable Zn-based BMs for cardiovascular applications.

| Surface modification method | Substrate | Techniques and modified layer | Main layer structure | Layer thickness | Efficiency of the coating | Ref. |
|-----------------------------|-----------|-------------------------------|----------------------|----------------|--------------------------|------|
| Organic coating             | Pure Zn (99.9%) | Immersing in MPS for 30 min followed by dip-coating in PLLA solution at room temperature. | PLLA | 1–12 μm | Increased corrosion resistance in vitro and in vivo. Decreased cytocompatibility with signs of toxicity and active neointima. | [222] |
|                             | Pure Zn foil (99.9%) | Immersing in the 2 mg/ml dopamine solution for 12 h. | Polydopamine | | Improved cell viability of human dermal fibroblasts, human aortic smooth muscle cells and human aortic endothelial cells. | [221] |
|                             | Pure Zn foil (99.9%) | Zn foils were incubated in the 2 mg/ml dopamine solution for 12 h. A 100 μm-thickness section of gelatin was produced, and affixed to the dopamine-coated Zn foil by bringing them into contact. Gelatin-covered foils were then immersed in 10 mM spermine ethanesulfonate for 20 min to cross-link the gelatin. | Polydopamine/gelatin | | Improved cell viability of human dermal fibroblasts, human aortic smooth muscle cells and human aortic endothelial cells. | [221] |
| Zn–1Mg                      | Zn–1Mg plates were immersed in 1 mol/L NaOH solution for 0.5 h at 60 °C. Then, they were immersed in 2 mL of 1 mol/L glutaraldehyde for 12 h at 37 °C. Finally, they were immersed in 2 mg/ml polyethylene glycol/chitosan copolymer solution for 12 h. | APTES/ phosphorylcholine chitosan copolymer | | | Increased corrosion resistance. Excellent hemocompatibility with hemolysis rate below 0.2%. Improved cell attachment and proliferation of human umbilical vein endothelial cells. | [225] |
| Air oxidation               | Pure Zn wire (~99.9%) | 360 °C for 1 h and 2 h in a regular furnace in air. | ZnO | 0.3–1.4 μm | | | [223] |
| Electropolishing            | Pure Zn wire (~99.9%) | 0.25 A/cm², 10 V, 2 min, electrolyte: 885 ml ethanol, 100 ml butanol, 109 g AlCl3·6H2O, 250 g ZnCl2, 120 ml H2O. | ZnO | 0.06–0.08 (± 0.05–0.15) μm | | | [223] |
|                             | Pure Zn (99.9%) | 0.45 A, ~90s, electrolyte: 885 mL C2H5OH, 100 mL C3H7OH, 109 g AlCl3·6H2O, 250 g ZnCl2. | ZnO | 5–10 μm | | | [223] |
| Anodization                 | Pure Zn wire (~99.9%) | I. Electropolishing: 0.25 A/cm², 10 V, 2 min, electrolyte: 885 ml ethanol, 100 ml butanol, 109 g AlCl3·6H2O, 250 g ZnCl2, 120 ml H2O. II. Anodization: ~4 A, 10 V, 1 min, electrolyte: 1 L oxalic acid (0.1, 0.3 or 0.5 M) solution. | ZnO | 5–10 μm | | | [223] |
|                             | Pure Zn (99.9%) | 0.45 A, ~90s, electrolyte: 885 mL C2H5OH, 100 mL C3H7OH, 109 g AlCl3·6H2O, 250 g ZnCl2. II. Anodization: ~4 A, 1min, electrolyte: 0.5 M (COOH)2. | ZnO and Zn2SiO4 | 28.6 ± 2 μm | 100% of the treated samples (9 out of 9) met the full biocompatibility benchmarks in vivo, leading to a failure rate of 0% (0 out of 9). | [226] |
| Microarc oxidation          | Zn–0.1Mg | 300 V, 120 s, electrolyte: 14 g/L Na2SiO3, 2 g/L KOH, 15 ml/L glycerol and 10 ml/L glycerol. | ZnO and Zn2SiO4 | 28.6 ± 2 μm | Improved blood compatibility with decreased hemolysis rate, lower lytic activity against red blood cells and lower platelet adhesion. Improved adhesion and viability of human umbilical vein endothelial cells. | [224] |
blood compatibility and cytocompatibility of human umbilical vein endothelial cells after MAO treatment.

4. Perspectives on the future surface modification strategies of Zn-based BMs

4.1. Potential surface modification methods of Zn-based BMs for orthopedic applications

Surface modification on BMs, such as Mg- and Fe-based alloys, has been extensively investigated in order to adjust their corrosion behavior without causing any damage to the bulk attributes. In terms of Mg-based BMs, the aim of the surface modification mainly focuses on the down regulation of the corrosion rate, alleviating the related complications caused by the rapid corrosion simultaneously [227,228]. In contrast, the surface modification on Fe-based BMs holds the opposite purpose [229,230]. Nonetheless, it seems that the demand of surface modification of Zn-based BMs for orthopedic applications stems from two issues based on the present research results, namely susceptible biocompatibility and retarded corrosion behavior. Firstly, excessive release of Zn ions can lead to an undesired biological response including in vitro cytotoxicity and in vivo delayed osseointegration despite a much lower ion concentration than that of Mg and Fe, as discussed above. Secondly, although Zn is featured by the more appropriate corrosion rate compared with Mg and Fe, it seems that the in vivo corrosion rates of Zn-based BMs are relatively slow in orthopedic environment (Table 2). From these perspectives, diverse surface modification methods can be taken into account to tackle the problems (Fig. 9).

4.1.1. Surface modification methods of accelerating biodegradation of Zn-based BMs

(1) Metallic elements ion implantation

Ion implantation can incorporate specific ions within the atomic network of surface without altering the bulk materials attributes [231]. Previous study has demonstrated that alloying Zn with IIA elements, such as Mg, Ca and Sr can improve the biocompatibility and accelerate the corrosion rates [132]. Yang et al. [145] also claimed that incorporating Mg into Zn matrix as sacrificial anode showed a beneficial effect on the in vitro and in vivo biocompatibility with decreased corrosion resistance. Such improved biocompatibility was attributed to the synergistic release of Zn$^{2+}$ and Mg$^{2+}$. Hence, it is hypothesized that incorporation of IIA elements on the surface of Zn-based BMs by ion implantation could improve the biocompatibility along with an increase in the corrosion rate.

(2) Polymer-based coatings

When served in the physiological environment, some polymer coatings such as PLA, PLGA and PDLLA degrade and release acidic degradation products [232]. The resultant local acidic environment is
expected to accelerate the corrosion of underlying BMs. Lin et al. [233] developed a layer of PDLLA coating on iron-based coronary scaffolds and successfully shortened the corrosion period of stent due to the formation of local acidic environment. Similar phenomenon of expedited corrosion has also been demonstrated by Yusop et al. when infiltrating PLGA into porous iron [234].

(3) Surface mechanical attrition treatment

Surface mechanical attrition treatment (SMAT) is one of the severe plastic deformation methods which can refine the grain size of treated metal surface to nanoscale. Meanwhile, the grain refinement and the interaction of dislocations after SMAT will bring about an improvement in the mechanical properties [235]. In addition, the increased surface roughness as well as high density of crystalline defects and micro cracks will impair the corrosion resistance of treated alloys, resulting in accelerated degradation behavior [236,237].

4.1.2. Surface modification methods of improving the biocompatibility of Zn-based BMs

(1) polymer-based coatings

Degradable natural polymers (e.g., chitosan, collagen and silk fibroin) have been widely applied on the surface of Mg-based BMs to improve their corrosion resistance and biocompatibility [232,238]. They can serve as physical barriers isolating the underlying metals from corrosive media [239]. Meanwhile, no acid degradation products will be released during degradation process. In addition, other functionalities, including self-healing [238], anti-inflammation [240] and osteoinduction [241], can also be achieved when loaded with functional agents.

(2) CaP-based coatings

Calcium phosphate (CaP) is the primary inorganic component in about 60% of native human bones [242]. Due to its superior biocompatibility and bioactivity, CaP has been intensively studied in the orthodontics and orthopedics as bone substitutes [243]. It shows a beneficial effect on the bone formation and generates chemical bonding to the newly-formed bone [244]. Recently, much attention has been focused on the application of CaP as coating material on the surface of Mg-based BMs for corrosion protection and biocompatibility improvement [245–248]. Diverse methods have been conducted to construct CaP coating on Mg-based BMs such as sol-gel [249], electrodeposition [250], hydrothermal deposition [251], pulsed laser deposition [252] and so on. Previous study has demonstrated that incorporating hydroxyapatite into Zn can significantly improve the in vivo osteogenesis [146]. Therefore, CaP coatings can be promising approach to improve the biocompatibility of Zn-based BMs with minimal effect on the bulk attributes.

(3) Nonmetallic elements ion implantation

The incorporation of nonmetallic elements (O, C, H, N, P, S, F, Si, and Se) into the surface of Zn-based BMs can also be considered on account of their high content in human body [198]. For instance, it is claimed that hydrated zinc phosphate is thermodynamically preferred in physiologically aqueous environment. Meanwhile, zinc phosphate coating has shown a stimulative impact on the biocompatibility of pure Zn [136]. Therefore, it is suggested that P ion implantation may improve the biocompatibility of Zn-based BMs by interaction of phosphate ions and released Zn ions in addition to the abundant existence and physio-logical functions of P in bone tissue.

Nevertheless, a blind increase in the corrosion resistance of Zn-based BMs after constructing physical barrier may compromise their advantages on the corrosion behaviors and result in a longer retention of implants despite an improvement in biocompatibility. Therefore, controversies have been aroused on the current surface modification methods of Zn-based BMs in orthopedic environment, dedicating efforts to intently improve the corrosion resistance. Generally speaking, controllable corrosion rate, either decreased or accelerated, should be under consideration based on outcomes of the healing process of injured tissue. In this way, composite coatings involving different surface modification methods should be developed. The design of a “smart” coating, which can alleviate the toxic influence of Zn$^{2+}$ and exploit the advantages of the degradation behavior of bulk materials, is expected in the future development of surface modification techniques of Zn-based BMs.

4.2. Potential surface modification methods of Zn-based BMs for cardiovascular applications

On the basis of the present research, Zn-based BMs shows the near-ideal in vivo corrosion behavior in cardiovascular environment. However, in spite of significant improvement of the mechanical properties compared with pure Zn, some alloy systems show signs of intimal activation with mild inflammation as discussed above. Meanwhile, the current implantation sites for the in vivo experiments are limited to the healthy blood vessels, which might result in a different healing process in comparison with that of lesioned vessels. Therefore, pathological models should be adopted to further verify the in vivo biocompatibility of Zn-based BMs. In terms of the clinical requirements, the cardiovascular implants should possess anti-hyperplasia function, hemocompatibility and re-endothelialization ability [253]. Herein, some potential and promising surface modification methods of Zn-based BMs for further cardiovascular applications have been put forward according to the clinical requirements, as shown in Fig. 9.

4.2.1. Surface modification methods of improving the anti-hyperplasia function of Zn-based BMs

(1) Drug-loaded coatings

Some anti proliferative drugs or inhibitors, such as paclitaxel [254], sirolimus [255], rapamycin [256] TNF-α antibody [257] and so on, are able to suppress the intimal hyperplasia. Meanwhile, such drug molecules can be incorporated into the polymer coatings to improve the anti-hyperplasia function. It is found that paclitaxel-loaded biodegradable film made of chondroitin sulfate and gelatin can reduce the neointima formation [258]. Besides, Shi et al. [259] prepared rapamycin-eluting PDLLA coating on Mg alloy. It is claimed that the modified stents exhibited favorable biosafety with comparable neo-intima formation to the commercial non-degradable drug-eluting stents.

(2) NO-releasing coatings

Nitric oxide (NO) plays an important role in the regulation of intimal hyperplasia. It can suppress the proliferation and migration of vascular smooth muscle cell (VSMC), stimulate the apoptosis of VSMC and inhibit leukocyte chemotaxis [260]. NO-releasing coatings have been utilized to prevent restenosis. Zhang et al. [261] constructed dopamine/Cu ion biomimetic coating on stainless steel stent. The biomimetic coating can generate NO locally and reduced neointimal formation in vivo.

4.2.2. Surface modification methods of improving the hemocompatibility of Zn-based BMs

(1) Drug-loaded coatings

Several drugs and biomolecules such as heparin [262], phosphor-yethylcholine [263], and albumin [264] can be used in the surface modification of stent to improve the blood compatibility. Lee et al. [265]
constructed heparin coating on the 3D printed PLA stents. It is found that heparin coating improved the hemocompatibility with reduced fibrinogen and platelet adhesion.

(2) Ion implantation

Fe–O film have been applied on the surface of pure Fe via plasma immersion ion implantation. The Fe–O film showed favorable hemocompatibility with only slight platelet activation [266]. Besides, it is also reported that incorporating Lanthanum (La) and Helium (He) into the surface had a beneficial effect on the blood compatibility. Zhu et al. [267] implanted La ion into pure Fe and demonstrated an improved hemocompatibility with decreased platelets adhesion, activation, aggregation and pseudopodium. In addition, Sugita et al. [268] implanted He ion into the collagen-coated Ti–Ni stents and exhibited excellent antithrombogenicity compared with the non-implanted collagen-coated stents.

4.2.3. Surface modification methods of improving endothelialization of Zn-based BMs

(1) Surface micro-patterning

Surface plays a significant role in the regulation of cellular cues including cell size, shape, adhesion, migration and proliferation [269]. The endothelial cell shape, which will influence the cell functions, can be controlled by surface micro-patterning independent of external forces [270]. Liang et al. [271] prepared biomimetic surface pattern based on the morphology of vascular smooth muscle cells on 316 L cardiovascular stent by femtosecond laser. A beneficial effect was found on the in vitro adhesion, proliferation and migration of endothelial cells as well as the in vivo re-endothelialization.

(2) Immobilization of functional biomolecules

Constructing functional coatings consisting of biomolecules such as REDV peptide [272], vascular endothelial growth factor (VEGF) [273], heparin [274] and anti-CD34 antibody [275] will have a beneficial impact on the re-endothelialization. Aoki et al. [276] demonstrated immobilization of CD34 antibody on stainless steel stent resulted in an accelerated re-endothelialization owning to the capture of endothelial progenitor cells.

5. Conclusions

In the past few years, Zn and its alloys have gained great interest as BMs owning to their favorable corrosion behavior and acceptable biocompatibility, following after Mg- and Fe-based BMs. However, in comparison with years of research and application in industrial field, the research of biomedical Zn-based materials is still in the initial stage. In this review, the state of the art of bulk Zn-based BMs and relevant surface modification strategies have been comprehensively summarized from the aspects of orthopedic and cardiovascular applications. Note that the previous surface modifications on Zn are mainly focused on the industrial applications regardless of the biosafety and degradation period, the challenges and future development directions of surface modification of Zn-based BMs for biomedical applications have also been discussed:

(1) In terms of orthopedic applications, the recently-developed Zn-based BMs exhibit dilatory corrosion in physiological environment. Besides, the low concentration threshold of Zn ion for cells and tissues also remains a concern. From this point of view, endeavor should be made to achieve accelerated degradation and controllable release of degradation products simultaneously. Therefore, various potential surface modification techniques have been proposed based on these two issues such as polymer-based coating, ion implantation and so on. Meanwhile, in contrast with one-way adjustment of corrosion behavior for the surface modification of Mg- and Fe-based BMs, composite coatings fabricated by the combination of different surface modification methods can be taken into account for Zn-based BMs to adjust the corrosion behavior and enhance the bone formation ability simultaneously.

(2) When it comes to the cardiovascular applications, some Zn-based BMs exhibited intimal activation with mild inflammation, which may impair the therapeutic effect of implanted devices. Meanwhile, the current implantation sites of Zn-based BMs are limited to the healthy blood vessels. Hence, further researches should be focused on the host response to the Zn-based BMs after being implanted in the pathological vessels in the future. Besides, in order to further improve the performance of Zn-based BMs, some potential surface modification technologies have been put forward to enhance the anti-hyperplasia function, hemocompatibility and re-endothelialization such as the drug-loaded coatings, ion implantation, surface micro-patterning and so on.

Declarations of competing interest

The authors declared that they have no conflicts of interest to this paper. We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with this paper.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant No. 51931001, 51901003), the International Cooperation and Exchange project between NSFC (China) and CNR (Italy) (NSFC-CNR Grant No. 52011530392), the Open Project of NMPA Key Laboratory for Dental Materials (Grant No. PKUSS20200401).

References

[1] D. Apelian, M. Paliwal, D.C. Herrschaft, Casting with zinc alloys, JMET (J. Med. Eng. Technol.) 33 (11) (1981) 12–20.
[2] M.T. Abou El-khair, A. Daoud, A. Ismail, Effect of different Al contents on the microstructure, tensile and wear properties of zinc-based alloy, Mater. Lett. 58 (11) (2004) 1754–1760.
[3] J.B. Bajat, V.B. Mišković-Stanković, N. Bibić, D.M. Drazić, The influence of zinc surface pretreatment on the adhesion of epoxy coating electrodeposited on hot-dip galvanized steel, Prog. Org. Coating 58 (4) (2007) 323–330.
[4] M.A. Arenas, C. Casado, V. Nobel-Pajol, J. Damborenea, Influence of the conversion coating on the corrosion of galvanized reinforcing steel, Cement Concr. Compos. 28 (3) (2006) 267–275.
[5] M. Fedel, M. Poddar, M. Olivier, F. Deflorian, Sebacic acid as corrosion inhibitor for hot-dip galvanized (HDG) steel in 0.1 M NaCl, Surf. Interface Anal. 51 (5) (2019) 541–551.
[6] S.M.A. Shibli, B.N. Meena, R. Remya, A review on recent approaches in the field of hot dip zinc coating, Surf. Coating. Technol. 262 (2015) 210–215.
[7] R.B. Figueira, C.J.R. Silva, E.V. Pereira, Hybrid sol–gel coatings for corrosion protection of galvanized steel in simulated concrete pore solution, J. Coating Technol. Res. 13 (2) (2016) 355–373.
[8] N. Pistofidis, G. Vourlias, D. Chalampalias, K. Chrysafis, G. Stergioudis, K. Polychroniadis, On the mechanism of formation of zinc pack coatings, J. Alloys Compd. 407 (1–2) (2006) 221–225.
[9] P.R. Seri, M. Banera, W.A. Egli, C.I. Elsner, A.R. Di Sarli, C. Davy, Effect on temporary protection and adhesion promoter of silane nanofilms applied on electro-galvanized steel, Int. J. Adhesion Adhes. 65 (2016) 88–95.
[10] Z.I. Ortiz, P. Diaz-Arista, Y. Mears, R. Ortega-Borges, G. Trejo, Characterization of the corrosion products of electrodeposited Zn, Zn-Co and Zn-Mn alloys coatings, Corrosion Sci. 51 (11) (2009) 2703–2715.
[11] R. Ramanauskas, P. Quintana, L. Maldonado, R. Pomes, M. Pech-Canal, Corrosion resistance and microstructure of electrodeposited Zn and Zn alloy coatings, Surf. Coating. Technol. 92 (1–2) (1997) 16–21.
[12] G. Tian, M. Zhang, Y. Zhao, J. Li, H. Wang, X. Zhang, H. Yan, High Corrosion protection performance of a novel nonfluorinated biomimetic superhydrophobic Zn-Fe coating with echinopsis multiplex-like structure, ACS Appl. Mater. Interfaces 11 (41) (2019) 38205–38217.
[74] M.R. Yuan, J.T. Lu, G. Kong, C.S. Che, Effect of silicate anion distribution in sodium silicate solution on silicate conversion coatings of hot-dip galvanized steels, Surf. Coat. Technol. 205 (19) (2011) 4470–4477.

[75] M. Hara, R. Ichino, M. Okido, N. Wada, Corrosion protection property of colloidal silicate film on galvanized steel, Surf. Coating. Technol. 169–170 (2003) 679–684.

[76] S.H. Zhang, G. Kong, Z.W. Sun, C.S. Che, J.T. Lu, Effect of formulation of silica-based coating on corrosion resistance of silicate coating on hot-dip galvanized steel, Surf. Interface Anal. 48 (3) (2016) 152–158.

[77] S. Dalbin, G. Maurin, R.P. Nogueira, J. Persello, N. Pommier, Silica-based coating for corrosion protection of electrogalvanized steel, Surf. Coating. Technol. 194 (2–3) (2005) 363–371.

[78] M.R. Yuan, J.T. Lu, G. Kong, Effect of SiO₂-NaO₄ molar ratio of sodium silicate on the corrosion resistance of silicate conversion coatings, Surf. Coating. Technol. 204 (8) (2010) 1229–1235.

[79] F. Jamali, D. Zaarei, D. Zarei, Effect of nano-silica on the corrosion behavior of silicate conversion coatings on hot-dip galvanized steel, Mater. Corros. 66 (5) (2015) 459–464.

[80] V.A. Paramonov, A.T. Moroz, N.G. Filatova, O.A. Karandzhyan, Chromateless silicate conversion coatings on hot-dip galvanized steel substrates, Prog. Org. Coating 63 (3) (2008) 330–337.

[81] M.F. Montemor, M.G.S. Ferreira, Cerium salt activated nanoparticles as fillers for silane films: evaluation of the corrosion inhibition performance on galvanised steel substrates, Electrochim. Acta 52 (24) (2007) 6976–6987.

[82] F. Bruscotti, A. Batac, I. De Graeve, M. Wenken, M. Biesemans, R. Willem, F. Fierens, J.J. Piets, T.W. Verpoest, H. Teye, Characterisation of thin water-based silane pre-treatments on aluminium with the incorporation of nano-dispersed CeO₂ particles, Surf. Coating. Technol. 205 (2010) 603–613.

[83] M.F. Montemor, W. Trabelsi, M. Zheludkevich, M.G.S. Ferreira, Modification of bio-silane solutions for nano-earth coatings for improved corrosion protection of galvanised steel substrates, Prog. Coating. Technol. 57 (1) (2006) 67–77.

[84] W. Trabelsi, P. Cecilio, M.G.S. Ferreira, M.F. Montemor, Electrochemical assessment of the self-healing properties of Cd-doped silane solutions for the pretreatment of galvanised steel substrates, Prog. Coating. Technol. 54 (4) (2005) 276–284.

[85] O.D. Lewis, G.W. Chrichtlow, G.D. Wilcox, A. deZeeuw, J. Sander, A study of the transport of zinc through the dentine layer of human teeth, J. Dent. Res. 72 (4) (1993) 758–769.

[86] M.F. Montemor, A.M. Cabral, M.L. Zheludkevich, M.G.S. Ferreira, The corrosion resistance of hot dip galvanised steel pretreated with Bis-functional silanes modified with microsilica, Surf. Coating. Technol. 209 (20) (2006) 2875–2885.

[87] A. Phanasaengprakob, V. Raja, Influence of curing temperature, silica nanoparticles and cerium on surface morphology and corrosion behaviour of hybrid silane coatings on mild steel, Surf. Coating. Technol. 203 (16) (2009) 2260–2271.

[88] H. Liu, S. Sun, S. Nakamura, T. Akiyama, R. Boccaccini, D. Gao, Silicon nitride deposition and characterization of chitosan/bioactive glass composite coatings on Mg alloy substrates, Electrochim. Acta 232 (2017) 456–464.

[89] G. Mani, M.D. Feldman, D. Patel, C.M. Agrawal, Coronary stents: a materials perspective, Biomaterials 28 (9) (2007) 1689–1701.

[90] Y.F. Zheng, X.N. Gu, F. Witte, Biodegradable metals, Mater. Sci. Eng., R 77 (2014) 1–34.

[91] J. Venezuela, M.S. Dargusch, The influence of alloying and fabrication techniques on the mechanical properties, biodegradability and biocompatibility of zinc: a comprehensive review, Acta Biomater. 87 (2019) 1–40.

[92] J.S. Forrestor, M. Fishbein, R. Heliant, J. Fajgan, A paradigm for restenosis on cell biology: clues for the development of new preventive therapies, J. Am. Coll. Cardiol. 17 (3) (1991) 758–769.

[93] H.S. Han, S. Loffredo, I. Jun, J. Edwards, Y.C. Kim, H.K. Seok, F. Witte, D. Mantovani, S. Glynn-Jones, Current status and outlook on the clinical translation of biodegradable metals, Mater. Today 23 (2019) 57–71.

[94] C. Chen, J. Chen, W. Zhao, L. Jin, P. Petričević, G. Yuan, W. Ding, J. Ge, E.R. Edelman, F. Migliavacca, In vivo and in vitro evaluation of a biodegradable magnesium vascular stent designed by shape optimization strategy, Biomaterials 32 (2011) 1941–1949.

[95] G. Chandra, A. Pandey, Biodegradable bone implants in orthopedic applications: a review, Biocybern. Biomed. Eng. 40 (2) (2020) 596–610.

[96] D. Zhao, F. Witte, F. Lu, J. Wang, J. Li, L. Qin, Current status on clinical applications of magnesium for orthopaedic implants: a review from clinical translational perspective, Biomaterials 112 (2017) 287–302.

[97] T. Kraus, S.F. Fischerauer, A.C. Hänzi, P.J. Ugwotit, J.F. Löfler, A. Weinberg, Biodegradable Mg-based alloys for use in osteosynthesis: an overview of their degradation and interaction with bone, Acta Biomater. 8 (3) (2012) 1230–1240.

[98] J.L. Wang, J.K. Xu, G. He, D.H. Chow, L. Qin, Biodegradable magnesium-based implants in orthopedics-A general review and perspectives, Adv. Sci. 7 (8) (2020) 1942244.

[99] T. Kraus, F. Fischerauer, M. Fiedler, E. Martinielli, J. Eichler, F. Witte, E. Willock, M. Schinnhammer, M. Meisich, P.J. Ugwotit, J.F. Löfler, A. Weinberg, Biodegradable Fe-based alloys for use in osteosynthesis: an overview of their degradation and interaction with bone, Acta Biomater. 8 (3) (2012) 2360–2379.

[100] S. Huang, J.H. Xu, C. He, D.H. Chow, L. Qin, Biodegradable magnesium-based implants in orthopedics-A general review and perspectives, Adv. Sci. 7 (8) (2020) 1942244.

[101] X.N. Gu, X.H. Xie, N. Li, Y.F. Zheng, L. Qin, In vitro and in vivo studies on a Mg-Sr binary alloy system developed as a new kind of biodegradable metal, Acta Biomater. 8 (3) (2012) 2360–2379.

[102] T. Kraus, F. Fischerauer, A.C. Hänzi, P.J. Ugwotit, J.F. Löfler, A. Weinberg, Biodegradable Mg-based alloys for use in osteosynthesis: an overview of their degradation and interaction with bone, Acta Biomater. 8 (3) (2012) 2360–2379.

[103] T. Kraus, F. Fischerauer, M. Fiedler, E. Martinielli, J. Eichler, F. Witte, E. Willock, M. Schinnhammer, M. Meisich, P.J. Ugwotit, J.F. Löfler, A. Weinberg, Biodegradable Mg-based alloys for use in osteosynthesis: an overview of their degradation and interaction with bone, Acta Biomater. 8 (3) (2012) 2360–2379.
stent in rabbit carotid artery model, J. Biomed. Mater. Res., Part B 107 (6) (2019) 1814–1822.

[164] S. Lin, Q. Wang, X. Yan, X. Ran, L. Wang, J.G. Zhou, T. Hu, G. Wang, Mechanical properties, degradation behaviors and biocompatibility evaluation of a biodegradable Zn–Mg–Cu alloy for cardiovascular implants, Mater. Lett. 234 (2019) 294–297.

[165] C. Chen, R. Yue, J. Yang, H. Huang, J. Niu, G. Yuan, Biodegradable Zn–1.5Cu–1.5Ag alloy with anti-aging ability and strain hardening behavior for cardiovascular stents, Mater. Sci. Eng. C 116 (2020) 111172.

[166] Z. Yang, H. Huang, J. Niu, L. Zhang, H. Jiang, J. Pei, T. Tan, G. Yuan, Design and characterization of novel biodegradable Zn–Cu–Mg alloys for potential biodegradable implants, Mater. Des. 117 (2018) 84–94.

[167] Z.-Z. Shi, J. Yu, X.P. Liu, L.N. Wang, Fabrication and characterization of novel biodegradable Zn–Mg–Cu–ZrO2 nanofilms, Mater. Sci. Technol. 34 (6) (2018) 1008–1015.

[168] R.J. Guillory, A.A. Oliver, E.K. Davis, E.J. Earley, J.W. Drelich, J. Goldman, Preclinical in vivo evaluation and screening of zinc-based degradable metals for endovascular stents, JOM 71 (4) (2019) 1436–1446.

[169] P.K. Bowen, R.J. Guillory II, E.R. Shearier, J.M. Seitz, J. Drelich, M. Bocks, F. Zhao, J. Goldman, Metallic zinc exhibits optimal biocompatibility for bioabsorbable endovascular stents, Mater. Sci. Eng. C 56 (2015) 467–472.

[170] L. Zhang, X. Tong, J. Lin, Y. Li, C. Wen, Enhanced corrosion resistance via phosphate conversion coating on pure Zn for medical applications, Corrosion Sci. 169 (2020).

[171] Y. Zhuang, Q. Liu, G. Jia, H. Li, G. Yuan, H. Yu, A biometric zinc alloy scaffold coated with brushite for enhanced cranial bone regeneration, ACS Biomater. Sci. Eng. 12 (2016) 893–902.

[172] G. Katarivas Levy, A. Kafri, Y. Ventura, A. Leon, R. Vago, J. Goldman, E. Aghion, P. Li, J. Qian, W. Zhang, C. Schille, E. Schweizer, A. Heiss, U.E. Klotz, R.J. Guillory, A.A. Oliver, E.K. Davis, E.J. Earley, J.W. Drelich, J. Goldman, Z. Shi, J. Yu, X.F. Liu, L.N. Wang, Fabrication and characterization of novel biodegradable Zn–Mg–Cu–ZrO2 nanofilms, Mater. Sci. Technol. 34 (6) (2018) 1008–1015.

[173] R. Vago, J. Goldman, Zinc phosphate as versatile material for bone tissue regeneration, Acta Biomater. 58 (2017) 515–526.

[174] W. Jin, H. Zhou, J.I. Li, Q. Ruan, J. Li, X. Peng, W. Li, P.K. Chu, Zirconium-based nanocoated structure on Mg–4Y–3RE alloy for corrosion retardation, Chem. Phys. Lett. 775 (2019) 111–115.

[175] E. Bolcske, P. Mariny, K. Stankевич, A. Kozelkaya, E. Shesterikov, I. Khodyrevska, M. Nasonova, D. Shishkova, Y.A. Kudryavtseva, Y. Anissimov, Surface modification of electropolymer poly(lactic) acid scaffolds by reactive magnetron sputtering, Colloids Surf. B Biointerfaces 162 (2018) 45–51.

[176] C.Y. Guo, A.T.H. Tang, J.P. Matinlinna, Insights into surface treatment methods of titanium dental implants, J. Adhes. Sci. Technol. 26 (1–3) (2012) 189–205.

[177] C.Y. Guo, J.P. Matinlinna, A.T.H. Tang, A novel effect of sandblasting on titanium surface: static charge generation, J. Adhes. Sci. Technol. 26 (23) (2012) 2603–2613.

[178] E.R. Shearier, P.K. Bowen, W.H. He, A. Drelich, J. Drelich, J. Goldman, F. Zhao, In vitro cytotoxicity, adhesion, and proliferation of human vascular cells exposed to pure Zn, Acta Biomater. 12 (2015) 634–642.

[179] A.A. Somali, R.J. Guillory, J. Seguin, J. Goldman, J.W. Drelich, Effect of PLLA coating on corrosion and biocompatibility of zinc in vascular environments, Surf. Innovations 5 (4) (2017) 211–220.

[180] A. Abdal-hay, N.A.M. Barakat, J.K. Lim, Hydroxyapatite-doped poly(lactic acid) nanoparticles as a seed for osseointegration of hierarchical micro/nanotopographic titanium fabricated by magnetron sputtering, Colloids Surf. B Biointerfaces 162 (2018) 45–51.

[181] Y. Sheng, H. Zhou, Z. Li, L. Chen, X. Wang, X. Zhao, W. Li, Improved blood compatibility and cytocompatibility of Zn–1Mg via plasma electrolytic oxidation, Materials 5 (2019).

[182] Y. Sheng, J. Yang, R. Hou, L. Chen, J. Xu, H. Liu, X. Zhao, X. Wang, R. Zeng, W. Li, J. Xie, Improved biocompatibility and degradation behavior of biodegradable Zn–1Mg by grafting ethynylphosphonic/phenylsilane chain (PGO) coating on silane pre-modified surface, Appl. Surf. Sci. 527 (2020).

[183] R.J. Guillory 2rd, M. Sikora-Jasinska, J.W. Drelich, J. Goldman, In vitro corrosion and in vivo response to zinc implants with electropolished and anodized surfaces, ACS Appl. Mater. Interfaces 11 (22) (2019) 19884–19893.

[184] I. Antoniac, F. Miculescu, C. Cotrut, A. Ficai, J.V. Rau, E. Grosu, A. Antoniac, C. Tescu, I. Cristescu, Controlling the degradation rate of biodegradable Mg–Zn–Mn alloys for orthopedic applications by electrophoretic deposition of hydroxyapatite coating, Materials 13 (2) (2020) 263.

[185] B. Istrate, J.V. Rau, C. Munteanu, I.V. Antoniac, V. Saceleanu, Properties and in vitro assessment of ZrO2-based coatings obtained by atmospheric plasma jet spraying on biodegradable Mg–Ca and Mg–Ca–Zr alloys, Ceram. Int. 46 (4) (2020) 15897–15906.

[186] H. Wang, Y. Zheng, C. Jiang, Y. Li, Y. Fu, In vitro corrosion behavior and cytocompatibility of pure Fe implanted with Ta, Surf. Coating. Technol. 320 (2019) 201–205.

[187] T. Huang, Y. Cheng, Y. Zheng, In vitro studies on silver implanted pure iron by metal vapor vacuum arc technology, Colloids Surf., B 142 (2016) 20–29.

[188] S.N. Nayab, P.H. Jones, I. Olsen, Effects of calcium ion-implantation of titanium on bone cell function in vitro, J. Biomed. Mater. Res. 83 (2) (2007) 296–302.

[189] L.Y. Li, L.Y. Cui, R.C. Zeng, S.Q. Li, X.B. Chen, Y. Zheng, M.B. Kannan, Advances in functionalized polymer coatings on biodegradable magnesium alloys - a review, Acta Biomater. 79 (2018) 29–36.

[190] W.J. Lin, D.Y. Zhang, G. Zhang, H.T. Sun, H.P. Qi, L.P. Chen, Z.Q. Li, R.L. Gao, W. Zheng, Design and characterization of a novel biocorrosible iron-based drug-eluting coronary scaffold, Mater. Des. 92 (2015) 72–79.

[191] A.H. Yusop, N.M. Daud, H. Nur, M.R. Kadir, H. Hermawan, Controlling the degradation kinetics of Mg alloys by poly(etherketoneketone) chain (PEKK) infiltration for use as medical temporary implants, Sci. Rep. 5 (2015) 11114.

[192] X. Meng, M. Duan, L. Luo, D. Zhan, B. Jin, Y. Jin, X.X. Rao, Y. Liu, J. Lu, The deformation behavior of AZ31 Mg alloy with surface mechanical attrition treatment, Mater. Sci. Eng. C 67 (2016) 646–652.

[193] N. Li, Y.D. Li, Y.X. Li, H.Y. Wu, Y.F. Zheng, Y. Han, Effect of surface mechanical attrition treatment on biodegradable Mg–1Ca alloy, Mater. Sci. Eng. C 35 (2014) 321–327.

[194] S. Bagnard, M.F. Molla, D. Kajane, R. Donnini, B. Hadzima, M. Guagliano, Accelerated biodegradation and improved mechanical performance of pure iron through surface grain refinement, Acta Biomater. 98 (2019) 88–102.

[195] P. Xinong, Z. Jia, W. Zhou, J. Yan, P. Wang, W. Wang, Y. Li, Y. Chen, Z. Guan, Z. Zheng, Osteogenic potential and degradation behavior of coating on biomedical Mg1Ca alloy, Acta Biomater. 92 (2019) 336–350.

[196] H. Seise, H. Virtanen, A.R. Boccaccini, Tackling Mg alloy corrosion by natural material coatings—a review, J. Biomed. Mater. Res. 104 (10) (2016) 2628–2641.

[197] X. Luo, X.T. Cui, Electrochemical deposition of conducting polymer coatings on magnesium surfaces inionic liquid, Acta Biomater. 7 (1) (2011) 441–446.
